INFRAFRONTIER Conference 2020

Targeting Cancer with Animal Models

October 7 to 9, 2020        Brussels, Belgium

Please note: Due to the COVID-19 pandemic, the conference has been rescheduled to 07 - 09 October. This site has been updated accordingly. 



Venue: Crowne Plaza Brussels - Le Palace

INFRAFRONTIER 2020 Conference will be a face-to-face event with remote streaming for attendees who will not be able to join us due to Covid-19 restrictions. 

Registration deadline: August 31, 2020

Next to cardiovascular diseases in the EU, cancer is the leading cause of death and one of the major contributors to premature deaths. In 2016, one quarter (26.0%, 13 million people) of the total number of deaths in Europe were caused by cancer.

The EC has taken a strong stand in the fight against cancer with the inception of its Europe Beating Cancer Plan and the Cancer Mission area for Horizon Europe framework beginning in 2021.

Mouse models are used in cancer research to explore the causality between cancer genes and carcinogenesis, and as models to develop and test novel therapies. Mouse models have become ideal models for precise individualized cancer therapy thanks to the advancements in CRISPR/Cas9-mediated genome editing, patient xenograft implantation and microbiota studies. 

The INFRAFRONTIER Conference 2020 ‘Targeting Cancer with Animal Models’ aims to showcase such innovative animal models used in cancer research and also introduce the Cancer Mission Board to the cancer research community. 

The main objectives of this conference will be to:

  • Present latest research on innovative cancer models
  • Showcase INFRAFRONTIER services for cancer research
  • Align the scientific strategy on cancer mouse models with the Horizon Europe Cancer Mission
Confirmed Speakers

 These speakers will present at INFRAFRONTIER Conference 2020:

  • Hellmut Agustin, German Cancer Research Center, DE
  • Tomi Mäkelä, Horizon Europe Cancer Mission and Helsinki Institute of Life Science, FI
  • Bernard Malissen, Centre for Immunophenomics (CIPHE), FR
  • Pirjo LaakkonenHelsinki Institute of Life Science, FI
  • Bodo Lange, CanPathPro, DE
  • Emmy Verschuren, Institute for Molecular Medicine Finland, FI
  • Leo PriceOcellO B.V., NL

The following Biomedical Research Infrastructures / consortiums will also present their efforts in cancer research:

  • BBMRI-ERIC - The European Research Infrastructure for biobanking that brings together all the main players from the biobanking field – researchers, biobankers, industry, and patients – to boost biomedical research
  • EATRIS-ERIC -  The European Infrastructure for translational medicine that helps to de-risk and add value to drug, vaccine or diagnostic development programme by providing fast, tailored access to cutting-edge enabling technologies in translational research
  • ECRIN - The European Clinical Research Infrastructure Network (ECRIN) is a not-for-profit intergovernmental organisation that supports the conduct of multinational clinical trials in Europe
  • EurOPDXThe EurOPDX Consortium is an initiative of translational and clinical researchers from Europe with the common goal of creating a network of clinically relevant models of human cancer, and in particular patient-derived tumor xenograft (PDX) models
  • Euro-BioImaging - The European Research Infrastructure for biological and biomedical imaging through which life scientists can access imaging instruments, expertise, training opportunities and data management services
  • EU-OPENSCREEN - The European Infrastructure of Open Screening Platforms for Chemical Biology that integrates high-capacity screening platforms throughout Europe and jointly uses a rationally selected compound collection
  • Instruct-ERIC - The-European Research Infrastructure in structural biology that provides open access to cutting edge high-end structural biology technologies and methods 

 Draft Agenda

The draft agenda can be found here. The meeting will start at noon (October 07) and end at noon (October 09).


Please use this link to book your accommodation: 

Note: Accommodation costs will not be reimbursed. 


Please register here. Registration deadline is August 31. We will provide a link for remote streaming if you decide to attend remotely. If feasible, we encourage you to join us in person for engaging discussions, interactive poster sessions and wider networking opportunities. The registration to attend in person is limited to 60 participants. 

 Abstract Submission

Submit your abstract for an oral presentation or poster during the registration and indicate your preference for one or the other.  All abstracts submitted will be considered for either an oral or poster presentation at the discretion of the Program Committee. Abstract submission deadline is August 10. Here are the guidelines

Statement on the COVID-19 situation

Concerning preparations for the INFRAFRONTIER Conference in Brussels, October 07 to 09, 2020

The INFRAFRONTIER Research Infrastructure is well aware of all the difficulties caused by the coronavirus (COVID-19) epidemic, and is observing all current development with utmost care.

Nevertheless, we hope that the pandemic situation will improve before the INFRAFRONTIER Conference 2020 scheduled for October 07 to 09, 2020 in Brussels, Belgium.

To account for the latest pandemic considerations, INFRAFRONTIER 2020 Conference will be a face-to-face event; however, we will provide remote streaming of the individual talks for all attendees who will not be able to join us due to Covid-19 restrictions. We take this situation very seriously, and will make sure that we are always compliant with Belgium's safety regulations. We encourage you to join us in person not only to take part in engaging discussions but also for poster sessions and wider networking opportunities, which will not be possible from remote streaming.

Parallelly, we will constantly monitor the situation, WHO statements, travel advice and official recommendations from local authorities on the coronavirus outbreak and assessing the potential impact on the conference and its participants. 

Should risk evaluations change, the participants will be informed as soon as possible.

As a responsible science-based organisation, we believe it is essential to do all we can to protect the health of participants of the Brussels Conference. To this end, we will be putting in place special measures to help mitigating the spread of the virus. 

We advise participants to pay attention to travel advice from their own country’s government and to check if they have adequate travel and health insurance in place.

Up-to-date WHO advice and facts can be found here: